Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Women with HER2 positive metastatic breast cancer whose cancer grows despite other standard therapies have a new treatment option available next month, now that the Food and Drug Administration approved the EMILIA study’s T-DM1.
NEW YORK (Reuters Health) - More young women are being diagnosed with advanced, metastatic breast cancer than were three decades ago, a new study suggests - although the overall rate of cancers in that group is still small.
(Reuters) - U.S. health regulators approved a new drug made by Roche Holding AG for some patients with late-stage metastatic breast cancer who fail to respond to other therapies.
An article in the New England Journal of Medicine with updated overall survival results from the international EMILIA study of T-DM1 was published two days following an announcement of accelerated FDA review for the medicine.
Findings from the CONFIRM clinical trial presented at the 2012 San Antonio Breast Cancer Symposium in December showed that increasing the dose of fulvestrant (Faslodex) from 250 mg to 500 mg for women with estrogen receptor-positive metastatic breast cancer increased median overall survival by 4.1 months. Overall survival is the time a person lives from the start of treatment until death from any cause.
In a study published in The New England Journal of Medicine, researchers suggest that anastrozole (Arimidex), taken in combination with fulvestrant (Faslodex), extends both progression-free and overall survival in hormone receptor-positive metastatic breast cancer.
A final data analysis of the study EGF104900, which compared lapatinib (Tykerb) plus trastuzumab (Herceptin) to lapatinib alone, found the combination therapy resulted in a significant increase in overall survival in women with HER2 positive metastatic breast cancer.
A new report indicates that the use of bevacizumab (Avastin) in the treatment of women with metastatic breast cancer slows the progression of the disease but has no impact on their overall survival, the length of time women live after receiving treatment, or on their quality of life.
New evidence suggests that osteonecrosis of the jaw is uncommon after treatment with bisphosphonates or denosumab (Xgeva), a lab-created protein used to prevent bone fractures in cancers that metastasized to the bone. Monitoring oral dental health may prevent or resolve osteonecrosis as a side effect, the study found.
Results from the international EMILIA study suggest a new effective treatment for HER2 positive metastatic breast cancer, using trastuzumab (Herceptin) linked with the potent chemotherapy DM1.